Search Results for "Sunitinib"

21:27 EST 5th March 2015 | BioPortfolio

Matching Channels


Matching News

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma

Dr Mark Beresford talks to ecancertv at ASCO GU 2015 reflecting on the initial results of the ASSURE trial where adjuvant treatment with sorafenib or sunitinib is used for localised renal carcinoma...

[Articles] Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial

Sunitinib is active in previously treated patients with thymic carcinoma. Further studies are needed to identify potential biomarkers of activity.

Maintenance Sunitinib Improved PFS in Extensive-Stage SCLC

In a phase II study, the use of maintenance sunitinib improved progression-free survival among patients with untreated extensive-stage small-cell lung cancer.

Sorafenib nor Sunitinib Effective As Adjuvant Kidney Cancer Therapy

Neither sunitinib nor sorafenib reduced disease recurrence in patients with locally advanced renal cell carcinoma (RCC) when these agents were given to patients as adjuvant therapy, according to the r...

Tackling renal cancer with a combination of autologous immunotherapy and sunitinib

Prof Figlin talks to ecancertv at ASCO GU 2015 about the use of sunitinib in renal cancer when combined with AGS-003, an autologous immunotherapy designed to induce an immune response to a patient...

Sunitinib Active in Advanced Thymic Carcinoma

Sunitinib is active in advanced thymic carcinoma, concludes the first clinical trial of the drug in heavily pretreated patients. Medscape Medical News

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma

Dr Naomi Balzer-Haas talks to ecancertv at ASCO GU 2015 about the initial results from the phase III ASSURE trial. It appears that adjuvant sorafenib or sunitinib do not benefit patients with unfavo...

Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

Findings from a federally funded study presented at the 2015 Genitourinary Cancers Symposium suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post...

Matching PubMed Articles

AXL as a modulator of sunitinib response in glioblastoma cell lines.

Receptor tyrosine kinase (RTK) targeted therapy has been explored for glioblastoma treatment. However, it is unclear which RTK inhibitors are the most effective and there are no predictive biomarkers ...

A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma.

Sunitinib has become a standard treatment agent for metastatic renal cell carcinoma (RCC) for several years. However, various adverse events have been reported. We present a rare adverse effect of hyp...

Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition.

The angiogenesis inhibitor sunitinib is a tyrosine kinase inhibitor that acts mainly on the VEGF and PDGF pathways. We have previously shown that sunitinib is sequestered in the lysosomes of exposed t...

Contribution of Plasma Proteins, Albumin and Alpha 1-Acid Glycoprotein, to Pharmacokinetics of a Multi-targeted Receptor Tyrosine Kinase Inhibitor, Sunitinib, in Analbuminemic Rats.

The present study investigated the role of the major plasma proteins, albumin and α1-acid glycoprotein (AAG), in the pharmacokinetics of sunitinib using Sprague-Dawley (SD) rats and analbuminemic rat...

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

Previously published pharmacokinetics (PK) models for sunitinib and its active metabolite SU12662 were based on a limited dataset or lacked important elements such us correlations between sunitinib an...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement